Business Of Biotech
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.
Episodes
293 episodes
Bringing Curative Cell Therapies To Market with Kite Pharma's Cindy Perettie
On this week's episode of the Business of Biotech, we're speaking with Cindy Perettie, Executive Vice President and Global Head at Kite Pharma, a Gilead-owned company focused on curing cancer with cell therapies. Perettie talks about scaling ce...
•
Episode 292
•
42:36
BoB@JPM: Brian Hilberdink, Boehringer Ingelheim
On this week's episode of the Business of Biotech, Brian Hilberdink, President of U.S. Human Pharma at Boehringer Ingelheim, returns to the show during the J.P. Morgan Healthcare Conference, and following his departure from LEO Pharma (see epis...
•
Episode 291
•
44:35
BoB@JPM: Ron Cooper, enGene
On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global ...
•
Episode 290
•
55:57
BoB@JPM: Marc Salzberg, M.D., Airway Therapeutics
The Business of Biotech was back in San Francisco for the J.P. Morgan Healthcare Conference (January 12 - 15) and this week we sit down with Marc Salzberg, M.D., CEO, CMO, and Board Chair at Airway Therapeutics, a company developing a recombina...
•
Episode 289
•
36:08
A Royalty Model For Value Creation With Zymeworks' Kenneth Galbraith
On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through partnerships with companies including Jazz Pharmaceu...
•
Episode 288
•
58:44
Life Science Connect Editors' Roundtable: Wrapping Up 2025 And Looking Ahead
This week's special holiday episode of the Business of Biotech brings seven chief editors from the Life Science Connect family together to talk about the life sciences industry topics, trips, and reporting that mattered most in 2025, and what e...
•
Episode 287
•
1:21:12
Building Cell Therapy Companies With Kenai Therapeutics' Nick Manusos
On this week's episode of the Business of Biotech, Nick Manusos, CEO at Kenai Therapeutics, talks about his experiences building cell therapy spinouts from FujiFilm Cellular Dynamics, learning from big pharma decision-making processes, and dosi...
•
Episode 286
•
46:39
Modernizing Clinical Trial Operations With Merck's Jennifer Sheller
On this week's episode of the Business of Biotech, Jennifer Sheller, SVP and Head of Global Clinical Trial Operations at Merck talks about simplifying trial protocols and what she likes about Merck's hybrid functional service provider model for...
•
Episode 285
•
55:39
Transforming Chronic Kidney Disease With ProKidney's Bruce Culleton, M.D.
On this week's episode of the Business of Biotech, Bruce Culleton, M.D., CEO at ProKidney, talks about moving from academic research to industry and the role a key mentor played in his career path. Bruce discusses his experiences as a first-tim...
•
Episode 284
•
55:36
Engineering B Cells With Immusoft's Sean Ainsworth
On this week's episode of the Business of Biotech, Sean Ainsworth, CEO and Chairman at Immusoft, talks about transitioning from the research bench to entrepreneurship, his M&A experiences as a biotech founder, and why engineered B cell ther...
•
Episode 283
•
53:51
Building A Cancer Pipeline In A Molecule With Actuate Therapeutics' Dan Schmitt
On this week's episode of the Business of Biotech, Dan Schmitt, President and CEO at Actuate Therapeutics, talks about building a company around elraglusib, a GSK-3β inhibitor for cancer. Dan describes his fast-fail approach to early product te...
•
Episode 282
•
51:25
Biotech Collaboration Strategy With IGI's Cyril Konto, M.D.
On this week's episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during the 'biotech winter,' closing a $700 million ...
•
Episode 281
•
58:41
Biotech Funding And IPO Temperature Check With Create Medicine's Allan Shaw
Allan Shaw, Chief Financial Officer and Chief Business Officer at Create Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market. We discuss the implications of recent blockbuster ...
•
Episode 280
•
57:01
Funding Tips And Moving From R&D To Commercial With Madrigal Pharmaceuticals' Mardi Dier
On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financi...
•
Episode 279
•
46:11
Emerging From Stealth With Vima Therapeutics' Bernard Ravina, M.D.
On this week's episode of the Business of Biotech, we're speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May with $60 million Series A financing to develop an oral candidate for dystonia, a m...
•
Episode 278
•
42:48
BoB in South Florida: Rich Daly, Catalyst Pharmaceuticals
On this week's episode — the last of our four-part series focused on South Florida — we catch up with Rich Daly, CEO at Catalyst Pharmaceuticals, a member of Life Science Leader's editorial advisory board and Miami-based location host ...
•
Episode 277
•
31:47
BoB In South Florida: Anthony Japour, M.D., iTolerance
On this week's episode of the Business of Biotech -- part three in a four part series recorded in-person at Catalyst Pharmaceuticals' Miami headquarters -- Anthony Japour, M.D., CEO at iTolerance, talks about his work as a physician treating in...
•
Episode 276
•
33:34
BoB In South Florida: Daniel Teper, NAYA Therapeutics
In this week's episode of the Business of Biotech -- part two in a four-part series recorded in-person at Catalyst Pharmaceuticals' Miami headquarters -- we're speaking with Daniel Teper, an entrepreneur and most recently, founder and CEO at NA...
•
Episode 275
•
33:08
BoB In South Florida: Raquel Cabo, Miami Biotech Collective
The Business of Biotech is on location in Miami this week! For the first episode in this four-part series on the biotech scene in South Florida, Raquel Cabo, Founder and President of the Miami Biotech Collective, talks about her experiences as ...
•
Episode 274
•
34:58
The Business Case For Health Economics And Outcomes Research With ISPOR's Rob Abbott
On this week's episode of the Business of Biotech, Rob Abbott, CEO of ISPOR, explains how startup and early-stage clinical drug development companies benefit from conducting health economics and outcomes research (HEOR), and not just with patie...
•
Episode 273
•
57:58
Cannabinoid And Psychedelic Combinations With Incannex Healthcare's Joel Latham
On this week's episode, Joel Latham, President and CEO at Incannex Healthcare, talks about developing cannabinoid and psychedelic combination therapies for conditions as diverse as sleep apnea, rheumatoid arthritis, and generalized anxiety diso...
•
Episode 272
•
57:27
Dye Drug Conjugates For Cancer With Lahjavida's Lyle Small
On this week's episode, Lyle Small, Founder and CEO at Lahjavida, a dye drug conjugate start-up, talks about creating the famous color-changing technology that turned the mountains blue on cold Coors Light beer cans, to launching a dye-drug con...
•
Episode 271
•
58:25
Investing In The Biostack With Modi Ventures' Sahir Ali, Ph.D.
On the Business of Biotech this week, Sahir Ali, Ph.D., founder and general partner at Modi Ventures, a family office investing at the intersection of technology and biology, talks about adapting the Markowitz model to improve returns and balan...
•
Episode 270
•
57:54
Improving Cardiovascular Outcomes With Immediate Therapeutics' Atul Deshpande, Ph.D.
On this week's episode, Atul Deshpande, Ph.D., CEO at Immediate Therapeutics, talks about partnering with American cities to conduct clinical trials during ambulance rides to the hospital, with the goal of preserving heart function and reducing...
•
Episode 269
•
1:04:36
Building A Biotech Incubator And Accelerator With Swiss Rockets Founder And CEO Vladimir Cmiljanovic, Ph.D.
On this week's episode, ex-handballer Vladimir Cmiljanovic, Ph.D., Founder and CEO at Swiss Rockets, talks about co-discovering bimiralisib with his sister Natasa Cmiljanovic, Ph.D. (and COO at Swiss Rockets), losing his company to a hostile ta...
•
Episode 268
•
52:07